206 related articles for article (PubMed ID: 16328595)
21. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
[TBL] [Abstract][Full Text] [Related]
22. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
[TBL] [Abstract][Full Text] [Related]
23. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance.
Würl P; Weigmann F; Meye A; Fittkau M; Rose U; Berger D; Rath FW; Dralle H; Taubert H
Scand J Gastroenterol; 1997 Nov; 32(11):1147-51. PubMed ID: 9399397
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
25. [Clinical significance of serum anti-p53 antibody measurement for colorectal cancer].
Kuwabara K; Kumamoto K; Ishibashi K; Ohsawa T; Kumagai Y; Baba H; Tsuji Y; Haga N; Ishida H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2167-9. PubMed ID: 23268012
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Cramer C; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2903-6. PubMed ID: 9329559
[TBL] [Abstract][Full Text] [Related]
27. Anti-FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer.
Kobayashi S; Hiwasa T; Ishige T; Kano M; Hoshino T; Rahmutulla B; Seimiya M; Shimada H; Nomura F; Matsubara H; Matsushita K
Cancer Sci; 2021 Feb; 112(2):847-858. PubMed ID: 33306856
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma.
Maehara Y; Kakeji Y; Watanabe A; Baba H; Kusumoto H; Kohnoe S; Sugimachi K
Cancer; 1999 Jan; 85(2):302-8. PubMed ID: 10023696
[TBL] [Abstract][Full Text] [Related]
30. [Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring].
Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Hayashi H; Iwasaki K; Sasagawa S; Chou A; Natsume T; Kouno T; Kondou S; Maeda T; Hori S; Suzuki T; Ochiai T; Isono K
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2189-94. PubMed ID: 10635303
[TBL] [Abstract][Full Text] [Related]
31. The use of tumor markers as predictors of prognosis in gastric cancer.
Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
[TBL] [Abstract][Full Text] [Related]
32. Serum anti-p53 antibodies and p53 protein status in the sera and tumors from bladder cancer patients.
Morita T; Tachikawa N; Kumamaru T; Nukui A; Ikeda H; Suzuki K; Tokue A
Eur Urol; 2000 Jan; 37(1):79-84. PubMed ID: 10671790
[TBL] [Abstract][Full Text] [Related]
33. Serum P53 Abs in HCC patients with viral hepatitis - type C.
EI-Emshaty HM; Gadelhak SA; Abdelaziz MM; Abbas AT; Gadelhak NA
Hepatogastroenterology; 2014 Sep; 61(134):1688-95. PubMed ID: 25436364
[TBL] [Abstract][Full Text] [Related]
34. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma.
Bourhis J; Lubin R; Roche B; Koscielny S; Bosq J; Dubois I; Talbot M; Marandas P; Schwaab G; Wibault P; Luboinski B; Eschwege F; Soussi T
J Natl Cancer Inst; 1996 Sep; 88(17):1228-33. PubMed ID: 8780633
[TBL] [Abstract][Full Text] [Related]
35. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer.
Kodera Y; Yamamura Y; Torii A; Uesaka K; Hirai T; Yasui K; Morimoto T; Kato T; Kito T
Am J Gastroenterol; 1996 Jan; 91(1):49-53. PubMed ID: 8561143
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of tumor-associated antigen (2H6 antigen) in detecting early stages of gastric cancer.
Harada H; Tsukada Y; Karasawa Y
Clin Chim Acta; 1994 Aug; 228(2):101-12. PubMed ID: 7527311
[TBL] [Abstract][Full Text] [Related]
38. p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue.
Broll R; Duchrow M; Oevermann E; Wellm C; Schwandner O; Schimmelpenning H; Roblick UJ; Bruch HP; Windhövel U
Int J Colorectal Dis; 2001 Feb; 16(1):22-7. PubMed ID: 11317693
[TBL] [Abstract][Full Text] [Related]
39. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases.
Neri M; Betta P; Marroni P; Filiberti R; Cafferata M; Mereu C; Ivaldi G; Montanaro F; Puntoni R; Paganuzzi M
Lung Cancer; 2003 Feb; 39(2):165-72. PubMed ID: 12581569
[TBL] [Abstract][Full Text] [Related]
40. Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma.
Cai HY; Wang XH; Tian Y; Gao LY; Zhang LJ; Zhang ZY
World J Gastroenterol; 2008 Jul; 14(25):4082-6. PubMed ID: 18609695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
